Publication of ZLT-L-007 IRB Approved Observational Study
Filed with ASX · · 9 pages · English
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- Zelira secures $1 Million At-the-Market Funding Facility
- Appendix 4D & FY25 Interim Financial Report
- Zelira receives $1,153,000 R&D Tax Incentive Scheme Refund
- Zeliras HOPE SPV Secures US$681,000 Fourth Funding Tranche
- September 2024 Quarterly Activities Report
Later from Zelira Therapeutics
- Zelira Therapeutics Secures R&D Loan Facility
- Preliminary Final Report
- Zelira receives $1,070,000 R&D Tax Incentive Scheme Refund
- Transformative US$33M Fundraising into Zeliras HOPE 1 SPV
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics